

RaySearch Laboratories Q1 - Demonstrating a strong profitability outlook

Redeye returns with a more in-depth take on the Q1 report. While sales and EBIT positively surprised, we leave our fair value range untouched. We repeat that the company's +25% EBIT margin for 2026e is highly achievable and consider it conservative.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

RaySearch Laboratories Q1 - Demonstrating a strong profitability outlook